The Medicines Manufacturing Innovation Centre is a collaboration between CPI, the University of Strathclyde, UK Research & Innovation Scottish Enterprise and founding industry partners AstraZeneca and GSK.

Based in the Advanced Manufacturing Innovation District in Renfrewshire, Scotland, the Medicines Manufacturing Innovation Centre is a state-of-the-art GMP facility. It will enable industry, academia, healthcare providers and regulators to work collaboratively to accelerate the development of new pharmaceutical manufacturing technologies, providing a clear pathway for their widespread adoption.

As we live in a society with rising life expectancy and an ageing population, one of the key challenges this poses is the increasing financial burden on the healthcare system as a whole. And this in turn has led to a pressing need for more cost-effective medication, which makes the potential of digital and data-enabled healthcare even more important. 

How the centre is addressing these challenges

The aim of the centre is to accelerate the development of a new generation of manufacturing processes and to help companies integrate these within their existing models. The evolution of pharmaceutical clinical development and manufacture is vital and there are many ways the centre can bring about change.

Novel techniques for producing patient-centric medicines, real-time release of drugs and integrated process analytics are all able to drive the transformation of medicines manufacturing and reduce the financial burden on payers and governments. Flexible and modular manufacturing for stratified medicine production, the ability to use next-generation technology in a GMP-capable environment and enabling efficient production can also protect future generations by bringing new medicines to market safely and quickly.

The Medicines Manufacturing Innovation Centre

Is the unique, state-of-the-art facility offering transformative solutions in small molecule and fine chemical manufacturing. Click here to read more.